{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:20:07Z","timestamp":1784179207063,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.leukres.2023.107368","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T03:21:00Z","timestamp":1691119260000},"page":"107368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed\/refractory patients with AML \u2013 A systematic review"],"prefix":"10.1016","volume":"133","author":[{"given":"A.","family":"Sherban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Fredman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Shimony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Yeshurun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Raanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gafter-Gvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Wolach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2023.107368_bib1","doi-asserted-by":"crossref","unstructured":"Lowenberg B., Downing J.R., Burnett A. Acute Myeloid Leukemia. https:\/\/doi-org.beilinson.idm.oclc.org\/10.1056\/NEJM199909303411407. doi:10.1056\/NEJM199909303411407.","DOI":"10.1056\/NEJM199909303411407"},{"issue":"6","key":"10.1016\/j.leukres.2023.107368_bib2","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood.V58.6.1203.1203","article-title":"Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B","volume":"58","author":"Rai","year":"1981","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2023.107368_bib3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/ajh.25214","article-title":"Acute myeloid leukemia: 2019 update on risk-stratification and management","volume":"93","author":"Estey","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"27","key":"10.1016\/j.leukres.2023.107368_bib4","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.leukres.2023.107368_bib5","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.leukres.2023.107368_bib6","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","article-title":"A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients","volume":"125","author":"Burnett","year":"2015","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.leukres.2023.107368_bib7","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2010.32.8500","article-title":"Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system","volume":"29","author":"R\u00f6llig","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.leukres.2023.107368_bib8","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2013.52.8562","article-title":"International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia","volume":"32","author":"Roboz","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2023.107368_bib9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.leukres.2023.107368_bib10","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","article-title":"Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)","volume":"100","author":"Byrd","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2023.107368_bib11","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood.V98.5.1312","article-title":"The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"Grimwade","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2023.107368_bib12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/MOH.0000000000000698","article-title":"Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes","volume":"29","author":"Shimony","year":"2022","journal-title":"Curr. Opin. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2023.107368_bib13","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/bjh.17974","article-title":"Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial","volume":"196","author":"Russell","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.leukres.2023.107368_bib14","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1046\/j.1365-2141.1997.4763281.x","article-title":"Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia","volume":"99","author":"Parker","year":"1997","journal-title":"Br. J. Haematol."},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2023.107368_bib15","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood-2022-164922","article-title":"Updated phase IIb results of venetoclax with FLAG-IDA in relapsed or refractory acute myeloid leukemia","volume":"140","author":"Desikan","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2023.107368_bib16","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.26601","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia","volume":"97","author":"DiNardo","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.leukres.2023.107368_bib17","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-022-04883-y","article-title":"Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis","volume":"101","author":"Wolach","year":"2022","journal-title":"Ann. Hematol."},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2023.107368_bib18","doi-asserted-by":"crossref","first-page":"9036","DOI":"10.1182\/blood-2022-168437","article-title":"Venetoclax (VEN) plus intensive chemotherapy (IC) with FLAG-IDA in patients (Pts) with newly diagnosed (ND) and relapsed\/refractory (R\/R) acute myeloid leukemia (AML)","volume":"140","author":"Abaza","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107368_bib19","article-title":"Fla-IDA Chemotherapy with or without Venetoclax in Patients with Relapsed\/Refractory Acute Myeloid Leukemia","author":"Shahswar","year":"2022","journal-title":"ASH"},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2023.107368_bib20","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1182\/blood-2022-157393","article-title":"Gimema AML1718 part 1: planned interim analysis of a safety run-in and phase 2 open-label study of venetoclax, fludarabine, idarubicin and cytarabine (V-FLAI) in the induction therapy of non low-risk acute myeloid leukemia","volume":"140","author":"Marconi","year":"2022","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2023.107368_bib21","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.3390\/cancers13246285","article-title":"Infections of venetoclax-based chemotherapy in acute myeloid leukemia: rationale for proper antimicrobial prophylaxis","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"i4919","key":"10.1016\/j.leukres.2023.107368_bib22","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.leukres.2023.107368_bib23","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1016\/S2352-3026(18)30051-6","article-title":"Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies","volume":"5","author":"Thanarajasingam","year":"2018","journal-title":"Lancet Haematol."},{"issue":"25","key":"10.1016\/j.leukres.2023.107368_bib24","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2023.107368_bib25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2023.107368_bib26","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1172\/JCI82908","article-title":"Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia","volume":"126","author":"Bhola","year":"2016","journal-title":"J. Clin. Invest"},{"issue":"10","key":"10.1016\/j.leukres.2023.107368_bib27","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.leukres.2023.107368_bib28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2023.107368_bib29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-020-0281-x","article-title":"Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold","volume":"10","author":"Ferrara","year":"2020","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.leukres.2023.107368_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/cancers14010022","article-title":"Venetoclax in relapsed\/refractory acute myeloid leukemia: are supporting evidences enough","volume":"14","author":"Brancati","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.leukres.2023.107368_bib31","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2023.107368_bib32","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol."},{"issue":"5","key":"10.1016\/j.leukres.2023.107368_bib33","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1016\/S2352-3026(22)00076-X","article-title":"Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study","volume":"9","author":"Lachowiez","year":"2022","journal-title":"Lancet Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2023.107368_bib34","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.leukres.2023.107368_bib35","unstructured":"Doehner P.D.H. A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2. clinicaltrials.gov; 2023. Accessed January 16, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04628026."},{"key":"10.1016\/j.leukres.2023.107368_bib36","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2023010276","article-title":"A Randomised Comparison of CPX-351 and FLAG-Ida in Adverse Karyotype AML and High-Risk MDS: The UK NCRI AML19 Trial","author":"Othman","year":"2023","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.leukres.2023.107368_bib37","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1038\/s41375-018-0148-3","article-title":"A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial","volume":"32","author":"Burnett","year":"2018","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:04:23Z","timestamp":1758935063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623006331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":37,"alternative-id":["S0145212623006331"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107368","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed\/refractory patients with AML \u2013 A systematic review","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107368","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107368"}}